Inhibikase Therapeutics (IKT) announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. Most recently Pigot served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: